This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia.
Method: An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD.
Results: General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods.
Conclusion: A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.
Footnotes
-
Study funding: The task force meeting was supported by contributions from the following participating companies: Allergan, Inc., AstraZeneca, ExonHit Therapeutics, Ipsen, Eli Lilly and Company, Lundbeck, Inc., Medivation, Inc., Pfizer Inc., Roche, Dr. Willmar Schwabe GmbH & Co., and Wyeth.
-
- AD
- Alzheimer disease
- ADAS-cog
- cognitive subscale of the Alzheimer's Disease Assessment Scale
- ADNI
- Alzheimer's Disease Neuroimaging Initiative
- aMCI
- amnestic mild cognitive impairment
- CDR-SB
- Clinical Dementia Rating Scale sum of boxes
- EMA
- European Medicines Agency
- FDA
- Food and Drug Administration
- MCI
- mild cognitive impairment.
- Received May 17, 2010.
- Accepted September 1, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Determining clinically meaningful decline in preclinical Alzheimer disease
Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypes
Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease
Using AD biomarker research results for clinical care